The Global Small Molecule Innovator CDMO Market Size is valued at 45.44 billion in 2022 and is predicted to reach 76.50 billion by the year 2031 at a 6.1% CAGR during the forecast period for 2023-2031.
The small molecule innovator CDMO (Contract Development and Manufacture Organization) market is a subset of the pharmaceutical business that provides contract services for small molecule drug development and manufacture. Small molecule pharmaceuticals are organic molecules with a molecular weight of fewer than 900 Daltons that are frequently synthesized.
The development and manufacturing organization (CDMO) market for small molecule innovators is a rapidly growing and dynamic sector that provides critical services to the pharmaceutical and biotech sectors. The increased demand for outsourcing drug development and manufacturing activities, as well as the increasing complexity of drug compounds, which necessitates specialized skills and equipment, are driving the market.
However, the pharmaceutical industry and CDMOs, like many others, encountered issues linked to remote work and preserving communication amid lockdowns and restrictions. These difficulties may have hampered project management and communication between innovative firms and CDMOs.
Competitive Landscape:
Some of the Small Molecule Innovator CDMO Market players are:
- Cambrex Corporation
- Bellen Chemistry
- Zhejiang LangHua Pharmaceutical Co., LTD.
- Raffles PharmaTech Co., Ltd
- Shanghai Mathcon Pharmaceutical Co., LTD
- Shanghai SynTheAll Pharmaceutical Co., Ltd.
- Wisdom Pharmaceutical Co., Ltd.
- Gear Pharma
- Hangzhou Aoya Biotechnology Co., Ltd.
- Desano Inc.
- Redhill Biopharma Ltd
- Shanghai Chemspec Corporation
- Zhejiang Chetou Pharmaceutical Co., Ltd
- Oncomed manufacturing a.s.
- Piramal Pharma Solutions
- CordenPharma International
- Wuxi AppTec
- Cambrex Corporation
- Recipharm AB
- Pantheon (Thermo Fisher Scientific)
- Lonza
- Catalent Inc.
- Siegfried Holding AG
- Boehringer Ingelheim
- Labcorp Drug Development
Market Segmentation:
The Small Molecule Innovator CDMO Market is segmented on the basis of product, stage type, customer type, and therapeutic area. Product segment includes Small Molecule API, Small Molecule Drug Product, Oral solid dose, Liquid Dos, Semi-Solid Dose, and Others.
The stage type segment includes Preclinical, Phase I, Phase II, Phase III, and Commercial. By customer type, the market is segmented into Pharmaceutical, Small, Medium, Large, and Biotechnology. The therapeutic area segment includes Cardiovascular disease, Oncology, Respiratory disorders, Neurology, Metabolic disorders, Infectious disease, and Others.
Based On Customer Type, The Pharmaceutical Segment Is Accounted As A Major Contributor In The Small Molecule Innovator CDMO Market
The pharmaceutical category is expected to hold a major share in the global Small Molecule Innovator CDMO Market in 2022. One of the primary drivers driving category growth is the increase in the number of new small molecule medication launches globally. Pharmaceutical businesses are increasingly interested in focusing on core skills while outsourcing non-essential operations such as medication manufacture and development; as a result, CDMO is actively expanding its manufacturing facilities.
The Small Molecule API Segment Witnessed Growth At A Rapid Rate
The small molecule API segment is projected to evolve at a rapid rate in the global Small Molecule Innovator CDMO Market. This expansion is mainly attributable to the increased need for small molecule developers. Furthermore, the US FDA has approved a large number of novel APIs in recent years. For example, in 2021, the FDA approved 50 novel molecular entities in the United States. Similar approvals in the future are expected to help the segment's growth.
In The Region, The North America Small Molecule Innovator CDMO Market Holds A Significant Revenue Share
The North America Small Molecule Innovator CDMO Market is expected to register the highest market share in terms of revenue in the near future. Technology advancements, low service costs, and the availability of trained labor at a lower cost than developed economies such as China and India are expected to drive regional market growth. One of the important drivers likely to drive growth throughout the projection period is an increased regulatory focus on quality control in manufacturing.
North America is predicted to increase rapidly during the projection period. It is a major contribution to the expansion of the Contract Development & Manufacturing Organisation (CDMO) market for small molecule API innovators. It is distinguished by the presence of several established pharmaceutical and biotechnology companies. Furthermore, rising R&D investments by life sciences and pharmaceutical firms are expected to boost demand for contract manufacturing in the region.
Small Molecule Innovator CDMO Market Report Scope:
|
Report Attribute |
Specifications |
|
The Market Size Value In 2022 |
USD 45.44 Bn |
|
Revenue Forecast In 2031 |
USD 76.50 Bn |
|
Growth Rate CAGR |
CAGR of 6.1 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Stage Type, Customer Type, And Therapeutic Area |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Piramal Pharma Solutions; Wuxi AppTec; Cambrex Corporation; Recipharm AB; CordenPharma International; Pantheon (Thermo Fisher Scientific); Siegfried Holding AG; Lonza; Catalent Inc.; Boehringer Ingelheim; Labcorp Drug Development. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
